PositiveID’s President, Lyle L. Probst, called in to SmallCapVoice.com to go over how PSID’s Firefly Dx system could assist in containing the Ebola virus in the United States and beyond. Mr. Probst also provided his personal insights into how PSID fits into the biological detection and diagnostics industry and much more. PositiveID’s Firefly Dx is a point-of-need, handheld system designed to deliver molecular diagnostic results using real-time PCR (polymerase chain reaction) chemistry. Firefly is being developed to meet the growing need in healthcare and molecular diagnostics markets for more rapid and accurate point-of-need diagnostics that will enable hospitals, physicians, military personnel, and others to save lives. Firefly can derive results from a sample in less than 20 minutes, at the point of need, compared to two to four hours for a lab device, which would enable accurate diagnostics leading to more rapid and effective treatment than what is currently available with existing systems.
PositiveID Corporation (PSID)